It is also important to keep track of IB's analysis, ratings and TPs, Vin. Their ratings have significant impact since the top shareholders are mostly funds/insti. The pessimistic and optimistic funds/insti are the driving force and not retailers. It will be big/small if your average price is way higher than IB's ratings.

Measures to reduce the high operating expenses. Hope to see more aggressive actions on GenM's US assets too - LAS VEGAS, Nev. (FOX5) - A major Strip casino announced Wednesday that less than 50 full-time employees have been laid off. Resorts World Las Vegas sent out a statement to FOX5 that the “decision is part of our ongoing efforts to optimize efficiency and maximize the exceptional experience we seek to deliver to our guests.” Full statement from Resorts World:
“To best position the company, we have made the difficult decision to restructure a portion of our operations by less than 50 full-time team members. We appreciate the contributions all affected team members have made. This decision is part of our ongoing efforts to optimize efficiency and maximize the exceptional experience we seek to deliver to our guests.”

No. I only hold genting..
I sold genm long time ago.. During the sue case between Disney.
But cheng, if genm keep plunge... Will effect genting share as well right..
Since alot investor less confident to lkt...
First genhk bankrupt then empire.. Now seem like genm soon..

I am ready to add on if it breaks below RM3.00 though it is unlikely, Vin. Market is bad due to tech and AI overvaluations and it will continue until it reaches attractive pricing. Tariffs are helping to speed up the corrections and DeepSeek helps to speed up the AI bubble :) Its safe in here as its neither a penny stock nor a tech stock.

Agreed, Vin. RWLV complaints closure is a big thing bcos sin stocks are sensitive to regulatory & taxes. Two events to watch out for in May (1) Q1'25 financial report - US segment performance (2) MSCI emerging market index review - it's important for Genting to stay in there; foreign funds visibility.

The stage has been setup by Trump to get Xi on board. However, Xi is not interested at all :) Xi's body language is pretty obvious as Xi did not attend Trump's inauguration ceremony :) So, Trump can only flex his muscles on other countries. He has increased the tariff on China to 20% and Xi hit back with 15% on US agriculture products. Trump repeatedly mention Xi is coming to China to negotiate but nothing from Xi's side on going to US to meet Trump :)

Need Trump's tariff to hit the market big time to the extend of confirmation of downturns and sin stocks historically outperform the broader market during this period :) at the back of consistent dividend and demand, without regulatory or higher taxes

Our discussion in previous post by jk was price impact ranging between 3.15 to 3.00 due to the cut in dividend from the qr. That's done deal and funds/insti would have bought it there. I agreed with Vin the bottom should not be lowered further as long as there is no negative/downside rerating for Gent.

Not sure on the exact timing, Vin. The previous articles I read from UK are pointing to possible decision in Apr. My personal opinion is that it makes no difference for the regulators to wait until Jun if they have gotten the additional information from TauRx back in Feb'25.

Cheng..what do you think the percentage of approval?
Others two brand of alzheimer just rejected from UK... This is the final one... TAURX!! :-)
Last time during the month before the taurx decision... Sure alot taurx news mention on social media.. And alot analysis gv higher tp... But this month seem like quite...

Tough call, Vin. Two main objectives from clinical trials - safety and efficacy. The biggest advantage of HMTM is that it is oral medication instead of IV and the safety part of it (no adverse events reported comparing to the other two). The regulators will have to decide whether they are happy with the data provided from the efficacy perspective. If yes, it should be approved accordingly. If no, they will still have to make a decision :)

There is no strong case to totally reject it in my personal opinion, Vin. The worst possible outcome could be exceptional circumstances / conditional marketing authorization instead of full marketing authorization given the needs in the UK market. Nevertheless, I will be eyeing to buy some if market sentiment pulls it down to below 3.15 before the decision.

Conditional approval is as good as full approval. The latter is quite rare over the history of trend of approval. In condition approval, the company will have to submit further evidence/studies during the period of selling the drug. At that time, it'll be very unlikely that the drug will be pull off the shelf

yes, 1.5 for genm is scary. all hell breaks loose. discounting for future events if you will. hopefully new CEO will provide clarity on GenM's interest on Thailand's IR. Going for both NYC full casino license and Thailand IR at the same time is too much given its previous track records of investment outside of Malaysia.

indeed, Jack. If I may - two consecutive investment failure - mashpee wampanoag and followed by increasing stakes in Empire from Kien Huat Realty. While the numbers from the latest qr showing it is still manageable, I am skeptical with GenM going for both Thailand and RWNYC at the same time. I will rather sit out and wait for clarity unless it becomes really cheap.

exactly Cheng. the final marketing authorisation of the drug will be a major catalyst and pave the road for more marketing authorisation in more countries, and hopefully US. But I doubt US FDA will approve it due to political play

Europe will be looking forward to any new Alzheimer drugs approval in the market as they have higher aging population. If TauRx receives the maa from MHRA, they can go for parallel submission to both EMA (Europe) and FDA (US) at the same time. https://worldpopulationreview.com/country-rankings/alzheimers-rates-by-country#top-10-countries-with-the-most-alzheimers

I just reached the gens last Saturday and donate 20sgd there, it's my last time to go, coz I got my PR, have to pay the levy in future. There still stable, compared with my last time , abit better than half years ago, harry porter still there. The expansion is on going , can see the building shape edy. The food court was closed for renovation.

Np, for casino wise, I think for low-middle income level no affected. A lot sg retired persons to spend their entertainment time in casino. But I have no idea for high income level, that we can't see, they play in VIP room.

another addition to the RWLV mgmt team - Resorts World Las Vegas (RWLV) has welcomed industry veteran Greg Shulman to the company in the role of executive vice president of international marketing. Greg's impressive career in the gaming industry is a testament to his leadership and relationships all over the globe," said Carlos Castro, COO and CFO of Resorts World Las Vegas. "He is widely regarded as one of the top player development executives in the industry, and we are thrilled to welcome him to our team as we continue to elevate our brand and expand our market reach."
Shulman will lead Resorts World Las Vegas' international casino marketing strategy, with a focus on high-end player development. He brings a wealth of experience to this role, having been a key member of the opening team at the Bellagio, where he held the title of executive director of marketing.
Most recently, Shulman served as the vice president of casino marketing for Palms Casino Resort, where he led enhancements to player development and guest relations. Shulman briefly departed the Vegas area to spearhead New Mexico's Sandia Resort & Casino reopening efforts as chief operating officer.

RWLV board chairman Jim Murren added: "Greg has a proven track record of executing marketing strategies that attract new audiences and drive financial growth. We are excited for Greg to continue expanding our global casino marketing efforts here at Resorts World Las Vegas, and we are confident he will be instrumental in supporting our ongoing success and development."

One week to go for the monthly UK regulators meeting. And TauRx on the other hand presented new data for HMTM in AD/PD conference - On 5 April 2025 at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, held in Vienna, Austria, during a symposium on “Tauopathies: challenges in targeting tau,” TauRx Therapeutics presented further analysis of data from its Phase III LUCIDITY (NCT03446001) trial, not previously presented, confirming the efficacy of LMTX (hydromethylthionine mesylate [HMTM]) for the treatment of mild cognitive impairment (MCI) and mild-to-moderate Alzheimer’s disease. LMTX is an oral small molecule that inhibits tau aggregation and has a secondary symptomatic effect of increasing levels of acetylcholine in the hippocampus. It is currently in pre-registration in the UK.